FDA Warns 4 Drug Companies Over Marketing Campaigns

The Food and Drug Administration has issued warning letters to four pharmaceutical companies over inaccurate claims they’ve made in their marketing campaigns. The four companies are Eli Lilly, Bayer, Amylin Pharmaceuticals, and Cephalon.
FDA cited drug maker Eli Lilly for its incomplete marketing claims concerning its antidepressant drug Cymbalta. The FDA noted that Lilly did not adequately display the potential side effects of the drug, a requirement for all approved pharmaceuticals.
In its warning to Cephalon, the FDA noted that the drug company neglected to provide the proper information concerning side effects for its lymphoma drug Treanda. Treanda has been associated with infections and skin reactions which have not been properly identified in the company’s marketing materials.
Amylin was charged with overstating the effectiveness of Byetta, a drug used to treat diabetes. In addition, Amylin has been promoting Byetta for unapproved uses, according to the FDA.
Bayer received a warning letter from the FDA due to its over-stated claims concerning its contraceptive Mirena.
While the FDA monitors and controls how pharmaceutical companies market their drugs, doctors are free to prescribe drugs for unapproved uses. However, the drug companies are forbidden by law to promote such uses of their drugs.